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DCE-MRI Perfusion and Permeability 
Parameters as predictors of tumor 
response to CCRT in Patients with 
locally advanced NSCLC
Xiuli Tao1,5, Lvhua Wang2, Zhouguang Hui2, Li Liu1, Feng Ye1, Ying Song1, Yu Tang2, Yu Men2, 
Tryphon Lambrou3, Zihua Su4, Xiao Xu4, Han Ouyang1 & Ning Wu1,5
In this prospective study, 36 patients with stage III non-small cell lung cancers (NSCLC), who underwent 
dynamic contrast-enhanced MRI (DCE-MRI) before concurrent chemo-radiotherapy (CCRT) were 
enrolled. Pharmacokinetic analysis was carried out after non-rigid motion registration. The perfusion 
parameters [including Blood Flow (BF), Blood Volume (BV), Mean Transit Time (MTT)] and permeability 
parameters [including endothelial transfer constant (Ktrans), reflux rate (Kep), fractional extravascular 
extracellular space volume (Ve), fractional plasma volume (Vp)] were calculated, and their relationship 
with tumor regression was evaluated. The value of these parameters on predicting responders were 
calculated by receiver operating characteristic (ROC) curve. Multivariate logistic regression analysis 
was conducted to find the independent variables. Tumor regression rate is negatively correlated 
with Ve and its standard variation Ve_SD and positively correlated with Ktrans and Kep. Significant 
differences between responders and non-responders existed in Ktrans, Kep, Ve, Ve_SD, MTT, BV_SD and 
MTT_SD (P < 0.05). ROC indicated that Ve < 0.24 gave the largest area under curve of 0.865 to predict 
responders. Multivariate logistic regression analysis also showed Ve was a significant predictor. Baseline 
perfusion and permeability parameters calculated from DCE-MRI were seen to be a viable tool for 
predicting the early treatment response after CCRT of NSCLC.
Lung cancer is the leading cause of cancer death in men and women worldwide1. More than 70% of non-small 
cell lung cancers (NSCLCs) are found as locally advanced unresectable disease or as advanced metastatic disease. 
Radiotherapy or concurrent chemo-radiotherapy (CCRT) has been an essential treatment modality2. However, 
even with the same clinical stage and pathological subtype, the prognosis of locally advanced NSCLC is different, 
which indicates tumor heterogeneity or different individual radio-sensitivity.
Blood supply to tumor is either through direct blood supply or vessel leakage. These vascular characteristics 
are known to influence radio-sensitivity through their effect on oxygen free radical generation, which interferes 
with the repair of radiation-induced DNA damage. The vascular characteristics of the tumors influence the extent 
of exposure to chemotherapy drugs and the level of drug activity by determining the intra-tumor pH and the 
ratio of quiescent cells within the tumor3,4. Various techniques can be applied to extract these hemodynamic 
information, such as ASL (Arterial Spin Labeling), DSC (Dynamic Susceptibility Contrast) and DCE (Dynamic 
Contrast-Enhanced) MRI. Unlike ASL and DSC, which are largely confined to neuroimaging, DCE-MRI can be 
applied to the whole body and provide both perfusion and permeability information5. As a non-invasive tech-
nique, DCE-MRI has been used as a predictor for tumor treatment response on many anatomies i.e. brain, breast 
etc5,6. DCE-MRI in lung cancer is an under-studied area, although previous DCE-MRI research was performed 
in lung by Naish et al.7 and CT perfusion research was performed by van Elmpt et al.8 The major difficulty for 
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dynamic scan to be performed in lung is breathing motion. Recent research on tackling this difficulty has been 
laid on using medical image registration9, which has been successfully applied to chest CT10. Research has been 
performed and concluded that it is quite necessary to have a motion control component i.e. image registration in 
DCE analysis steps to ensure high parameter accuracy11,12.
We conducted a prospective study to investigate whether baseline DCE-MRI perfusion and permeability 
parameters can provide useful information to predict CCRT response in patients of NSCLC.
Patients and Methods
Patients. This single-center prospective study was approved by the Ethics Committee of Cancer Hospital of 
Chinese Academy of Medical Sciences, and informed consents were obtained from all patients. This study was 
conducted in accordance with the Declaration of Helsinki. From January 2013 to April 2015, 40 consecutive 
NSCLC patients staged IIIA or IIIB, who planned to receive CCRT for lung cancer in our hospital were prospec-
tively recruited to this study. To determine the clinical stage, all of the 40 patients underwent chest CT, brain 
MRI, skeletal scintigraphy, and abdominal ultrasonography before therapy. The inclusion criteria were as fol-
lows: (a) biopsy-proven NSCLC, (b) the largest diameter of the pulmonary mass was 2.0 cm or larger, (c) no his-
tory of prior chemotherapy or radiotherapy or other therapy, (d) no contraindications for MR examination, and 
(e) agreement to participate in the study. All participants underwent DCE-MRI before CCRT within 1 week. The 
follow-up MR or CT scan was obtained at 1 month after the end of radiation therapy (when the total dose reached 
60 Gy) to assess the tumor response to the therapy. Four patients who changed treatment regimen or terminated 
CCRT were excluded due to metastases or other serious disease during CCRT. Thus, the final cohort included 36 
patients. Patient characteristics are listed in Table 1.
MRI Protocol. All MR examinations were performed on a 3.0 T scanner (Discovery MR750 3.0 T, USA) 
by using an eight-tunnel body phased-array coil. Multi-flip angles (3°, 6°, 9 ° and 12°) were first performed in 
the axial plane encompassing the entire tumor volume before dynamic scanning to determine pre-contrast 
T1 mapping. Dynamic sequence (3-Dimensional T1W fast spoiled gradient echo with repetition time/echo 
time = 2.9 ms/1.3 ms, flip angle = 12°, section thickness = 4.2 mm, gap = 0 mm, section number = 24) was then 
performed with a 4 s tempo and continued for 168 s (42 phase). During dynamic acquisition, patient took a breath 
for every 12 s. After the first three dynamic scans were performed, contrast agent (Omniscan, GE Healthcare) was 
injected at a dose of 0.1 mmol/kg of body weight with the injecting rate of 2.0 ml/s by power injector. Then the 
delayed phase was performed in the axial and coronary plane, which covered the area from the thoracic inlet to 
the adrenal glands.
Prior to DCE-MRI, T1-and T2-weighted images were obtained in the transverse plane in each 
patient. Pulse-gated T1-weighted fast spin echo images (repetition time/echo time = 600–900 ms/5.8 ms, 
matrix = 288 × 192) and respiratory-gated T2-weighted fast spin echo images [repetition time/echo 
time = (6000 ms–8000 ms)/85 ms, matrix = 288 × 224] were obtained with FOV of 360 mm–400 mm, section 
thickness of 6 mm, and gap of 1 mm encompassing the thoracic inlet through the adrenal glands routinely.
Image Analysis. Firstly, motion within multi-flip angle data and dynamic data were pre-processed by using 
a mutual-information based nonlinear registration algorithm. Quality of image registration was assessed sub-
jectively by two reviewers (S.Y. and L.L. with 10 and 12 years of experience in MR imaging, respectively) in 
consensus according to a three category scoring system: A score of 3 = good, a score of 2 = moderate, and a score 
of 1 = poor. The rating was determined on the basis of the registration quality, possible mis-registration artifact, 
and architectural distortion of the tumor and vessel branches13. Secondly, pharmacokinetic analysis was carried 
out on motion corrected data, using in-house developed software, Omni-kinetics (GE Healthcare, Life Science, 
China). Thirdly, arterial input function (AIF) was obtained by placing a ROI on thoracic aorta on transverse plane 
in the peak arterial enhancement phase14,15. We used an accelerated version of Tofts model, which is the Extended 
Tofts Linear model16, to generate permeability parameters (Ktrans: endothelial transfer rate, min−1; Kep: reflux rate, 
min−1; Ve: the fractional extracellular extravascular space (EES) volume, 0 < Ve < 1, dimensionless; Vp: fractional 
plasma volume, 0 < Vp < 1) and de-convolution method with delay correction17 was used to generate perfusion 
parameters (BF: blood flow, ml/100 ml/min; BV: blood volume, ml/100 ml; MTT: mean transit time, s).
Tumor ROI was placed by two radiologists (S.Y. and L.L. with 10 and 12 years of experience in MR imaging, 
respectively) in consensus. They went through the scan data and selected the slice with maximum tumor area. 
A ROI was manually drawn around the whole tumor, where the unenhanced and enhanced images were both 
reviewed to determine tumor boundary and avoid the presence of large vessels, and/or necrotic area(s).
Characteristics Number of patients, %










Table 1.  Clinical characteristics of patients (n = 36).
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Clinical Treatment and Tumor Response Assessment. All 36 patients underwent CCRT used stere-
otactic body radiation therapy with total radiation dose of 60 Gy in 30 fractions of 2 Gy each and chemotherapy 
with a combination of carboplatin and etoposide. The follow-up MR or CT scan was obtained at 1 month after the 
end of radiation therapy (when the total dose reached 60 Gy) to assess the tumor response to the therapy. Tumor 
size was defined as the maximum diameter measured on the largest area of whole tumor. Final tumors regression 
rate (%) was calculated according to the following equation: 100 × (pre-treatment size − post-treatment size)/
pretreatment size.
According to the RECIST1.1 criteria18, tumor response after therapy was classified as follows: complete 
response (CR), partial response (PR), stable disease (SD) or progressive disease (PD). Patients with a CR or PR 
were further classified as responders; the patients with SD or PD were further classified as non-responders.
Statistical analysis. The parameters were expressed as mean ± standard deviation (SD). The SD represents 
the heterogeneity of tumor parameters distribution (e.g., Ktrans_SD). Analysis was performed after ruling out zero 
values of Ktrans to exclude non-perfused/necrotic regions, for which the pharmacokinetic model is not valid.
SPSS for Windows software (SPSS, version 17.0) was used for all data analysis. Mann-Whitney U test (MW) 
was used to compare parameters between responders and non-responders. The relationship between quanti-
tative parameters and tumor regression rate after CCRT was evaluated by Spearmen’s correlation analysis. The 
value of parameters on predicting responders were calculated by receiver operating characteristic curve (ROC). 
Multivariate logistic regression analysis was conducted to find the independent variables. A P value less than 0.05 
was considered as statistically significant. Statistical tests were based on a two-sided significance level set at 0.05.
Results
General. A total of 36 patients were eventually enrolled. Clinical characteristics for these patients are shown in 
Table 1. Mean tumor size was (4.7 ± 1.5) cm (range 2.3 cm–7.4 cm). The median interval between MRI and initial 
therapy was 3 days (range 1day–6 days). After CCRT, 21 patients were classified as responders and 15 patients 
were classified as non-responders. The mean tumor size after treatment was (2.6 ± 1.3) cm (range 0.5 cm–5.1 cm). 
The quality of all motion corrected images were graded as good (31/36) or moderate (5/36).
Baseline permeability and perfusion parameters in responders and non-responders. The 
correlation between baseline permeability parameters and clinical response of NSCLC to CCRT are summa-
rized in Table 2. Responders had higher Ktrans and Kep than non-responders, whereas responders had lower Ve 
than non-responders. Tumor regression rate after treatment was positive correlated with pre-treatment Ktrans 
(P = 0.004) and Kep (P = 0.041), and was negative correlated with pre-treatment Ve (P = 0.008). The baseline 
enhanced images and color maps of permeability parameters are shown in Fig. 1.
The correlation between baseline perfusion parameters and clinical response of NSCLC to CCRT are summa-
rized in Table 3. Responders had shorter MTT [(34.2 ± 8.1) s vs. (41.9 ± 8.3) s, P = 0.011] than non-responders. 
However, there was no correlation with tumor regression rate and pre-treatment perfusion parameters. Patients 
with lower pre-treatment BV_SD and MTT_SD tend to have a good response (P < 0.05). The baseline enhanced 
images and perfusion parameters color maps are shown in Fig. 2.
The receiver operating characteristic curve (ROC) and multivariate logistic regression analysis 
of kinetic parameters. The permeability and perfusion parameters, which showed good prediction capa-
bilities to distinguish between responders and non-responders, were further analyzed by using receiver operating 
characteristic curve as in Table 4 and Fig. 3. ROC indicated that Ve has the best differentiation ability. By setting 
threshold of Ve to 0.24, the specificity, sensitivity and accuracy were 85.7%, 80.0% and 83.3%, with area under 
curve (AUC) of 0.865 (P < 0.001).
The multivariate logistic regression analysis showed that Ve was a significant predictor for estimating the 
responders. Details are shown in Table 5.
Discussion
T1W DCE-MRI has been extensively used in monitoring tumor response to antiangiogenic and vascular dis-
rupting agents, radiotherapy and chemotherapy6,19. It appears to be a useful tool in the investigation of tumor 
Permeability parameters
Tumor regression (n = 36)
Responders (n = 21) Non-responders (n = 15)
Responders vs. Non-responders
r value P value P value z value
Ktrans (min−1) 0.474 0.004 0.40 ± 0.15 0.26 ± 0.15 0.002 − 3.118
Kep (min−1) 0.342 0.041 2.13 ± 0.93 1.31 ± 0.50 0.004 − 2.857
Ve − 0.435 0.008 0.20 ± 0.04 0.26 ± 0.05 0.001 − 3.252
Vp − 0.052 0.762 0.05 ± 0.03 0.05 ± 0.03 0.797 − 0.258
Ktrans_SD 0.060 0.766 0.18 ± 0.07 0.22 ± 0.20 0.863 − 0.201
Kep_SD 0.176 0.381 0.89 ± 0.54 0.69 ± 0.29 0.386 − 0.904
Ve_SD − 0.408 0.035 0.06 ± 0.02 0.09 ± 0.04 0.005 − 2.751
Vp_SD 0.074 0.713 0.03 ± 0.02 0.03 ± 0.01 0.675 − 0.439
Table 2.  Baseline permeability parameters and clinical response.
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microvascular structure and heterogeneity, which potentially improve sensitivity to subtle drug effects and pro-
vide additional understanding of tumor biology. However, this technique was not fully explored in lung cancer 
due to breathing motion. In our prospective study, we incorporate a medial image registration component to 
ensure better parameter accuracy and investigate if DCE-MRI can be a predictor of tumor response for patients 
with locally advanced lung NSCLC.
The pharmacokinetic parameters can be affected by the application of arterial input function (AIF)14,15. To 
incorporate the AIF data, several approaches have been proposed, such as reference experimentally derived 
AIFs, manual selection of individual AIFs, population-averaged AIFs or automatically extracted personalized 
AIFs14,15,20,21. Reference experimentally derived AIFs or population averaged AIFs mainly used for low temporal 
DCE-MRI protocol i.e. breast22. The application of automatically extracted personalized AIFs is confined to var-
ious factors, such as motion artifacts, the pulse of aorta, enhancing anatomical structures adjacent to the aorta 
and temporal resolution14,15. Therefore, we used a manual selection of individual AIFs with an ROI placed on 
thoracic aorta on transverse plane in the peak arterial enhancement phase. Compared with other publications in 
DCE-MRI on lung cancer, similar order of magnitude in parameters was obtained in our results. For example, one 
clinical DCE-MRI paper on lung cancer23, gave Ktrans values in the range of 0.058 to 2.703 min−1, with a median of 
about 0.5 min−1 and close to our results. Another study24 achieved same order of magnitude as ours but smaller in 
Figure 1. A 65-year-old man with lung squamous cell carcinoma, who partial responded to concurrent 
chemo-radiotherapy and classified as responders was shown (Ktrans mean value, 0.65 min−1; Kep mean value, 
1.88 min−1; Ve mean value, 0.21; Vp mean value, 0.01). 
Perfusion parameters Responders (n = 21) Non-responders ( n = 15)
Responders vs. Non-responders
P value z value
BF (ml/100 ml/min) 46.7 ± 13.1 39.0 ± 19.2 0.070 − 1.813
BV (ml/100 ml) 24.3 ± 6.5 23.4 ± 7.7 0.585 − 0.546
MTT (s) 34.2 ± 8.1 41.9 ± 8.3 0.011 − 2.551
BF_SD 13.5 ± 5.2 14.5 ± 5.4 0.639 − 0.479
BV_SD 5.8 ± 2.8 9.6 ± 2.2 0.002 − 3.007
MTT_SD 8.2 ± 4.5 14.0 ± 3.9 0.001 − 3.045
Table 3.  Baseline perfusion parameters and clinical response.
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numbers (mean Ktrans = 0.125 min−1, mean Kep = 1.194 min−1) in permeability parameters. Neither of the above 
two studies showed BV or MTT values.
Kelly et al.25 evaluated KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced 
non-small-cell lung cancer receiving sorafenib. In that study, Kep demonstrated a significant predictive value for 
overall survival (OS, P = 0.035) and progression free survival (PFS, P = 0.029). The accuracy of pharmacokinetic 
parameters is very sensitive to patient motion. Kep is considered more robust than the other parameters in the 
presence of patient motion26. To reduce image motion in time domain, non-rigid registration was performed in 
our study, and subjective evaluations on image registration showed that all registered images had good or moder-
ate image quality. From statistical results it can be seen that, many baseline perfusion and permeability parameters 
can predict early tumor response. Therefore, we find more statistical valuable parameters than previous Kelly 
et al.25 research, although our experiment is in the same organ but different end point. It is highly recommended 
to have a motion control component in the experiment such as image registration method.
The pre-treatment permeability parameters Ktrans and Kep were significantly higher in responders than in 
non-responders. These results might support the hypothesis that high Ktrans and Kep values indicate high blood 
supply and therefore better oxygenation and showed efficient radiation sensitivity27. Tumors with poor blood sup-
ply will lead to chronic hypoxia of tumor cells, which influence radio-sensitivity through their effect on oxygen 
free radical generation by interfering with the repair of radiation-induced DNA damage, and thereby promot-
ing the transfer of tumor cells into subtypes with more resistance to chemotherapy and radiation regimens28–30. 
Figure 2. A 62-year-old man with lung adenocarcinoma, who was stable to concurrent chemo-
radiotherapy and classified as non-responders was shown (BF mean value, 19.8 ml/100ml/min; BV mean 
value, 22.3 ml/100 ml/min; MTT mean value, 59.2 s). 
Parameters AUC Threshold Sensitivity (%) Specificity (%) Accuracy (%)
Ktrans (min−1) 0.808 0.28 76.2 80.0 77.8
Kep (min−1) 0.767 1.60 66.7 73.3 69.4
Ve 0.865 0.24 85.7 80.0 83.3
MTT (s) 0.752 37.3 73.3 71.4 72.2
Table 4.  Values of baseline parameters on predicting responders. AUC, area under curve.
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Tumors with a higher level of permeability are suggested to be better oxygenated, resulting in better access to the 
chemotherapeutic drug and better radio-sensitivity.
To date, several studies have evaluated the correlation between quantitative DCE-MRI permeability parame-
ters and tumor response to radiotherapy in malignant tumors, and conflicting results have been reported. Zahra 
et al.31 reported that pre-treatment Ktrans and Kep had a significant correlation with tumor response in cervix can-
cer. Ahn et al.32 found that the good response group tended to show lower pretreatment Kep and higher pretreat-
ment Ve than the poor response group in a human colorectal cancer xenograft. However, Gu et al.33 reported in 
their rectal cancer study that DCE-MRI parameters at baseline were worthless to differentiate between responders 
and non-responders. These contrary results may due to small sample size (n = 5–13), different clinical staging 
of patients, different clinical treatment programs or other mixed factors. Our study selected locally advanced 
non-small cell lung cancer (stage III ) with no treatment history as the object of research, and all patients con-
ducted MR examination using the same regimen at the same time point, largely excluded the confounders above.
It is worth mentioning the value of baseline Ve on predicting responders, which is different to previous studies. 
Although Ellingsen et al.34 reported that there was no association between the values of pre-treatment Ve and 
hypoxia in cervical carcinoma xenografts, Kim et al.35 shown that the early increase of Ve associated with tumor 
regression of cervical cancer to radiotherapy. Also Cheng et al.36 had a similar result in Lewis lung carcinoma 
Figure 3. ROC curves for differentiation of responders from non-responders based on the pre-treatment 
Ktrans, Kep, Ve and MTT, the area under curve (AUC) was 0.808, 0.767, 0.865 and 0.752 respectively. 
P Value OR
95% CI for OR
Lower Upper
Ktrans (min−1) 0.086 0.000 0.000 6.035
Kep (min−1) 0.667 0.449 0.012 7.289
Ve 0.006 2.869 2.342 3.515
MTT (s) 0.977 1.002 0.850 1.183
Table 5.  Multivariate logistic regression model for estimating the responders. OR, odds ratio; CI, 
confidence interval.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:35569 | DOI: 10.1038/srep35569
(LLC) tumor that the early increase in Ve and ADC correlated with tumor control. O’Connor et al.37 reported 
that, high median Ve was associated with greater CRC liver metastasis shrinkage following bevacizumab and 
FOLFOX-6, and argue that median Ve is an estimate of the extracellular extravascular space affected by fac-
tors including cell size, number, and packing density. The high median Ve may represents a direct estimate of 
the distribution space to which a contrast agent or drug can be delivered, which may indicate the potential for 
greater extravasations of chemotherapy and bevacizumab into the extracellular extravascular space. We assume 
that lower values of Ve indicate higher cell density and, hence, lower rates of necrosis and more viable tissue. We 
may explain this result using the apparent diffusion coefficient (ADC) derived from diffusion-weighted imaging 
(DWI), which has been shown to correlate inversely with tissue cellularity38. Studies of a few carcinomas have 
shown that cellular tumors with low baseline ADC values respond better to chemotherapy or radiation treatment 
than tumors with high pretreatment ADC values39–41. Although we did not find any accurate reports interpreting 
the relationship between Ve and ADC values, further studies should be performed.
From perfusion aspect, the pre-treatment values of MTT are also promising, which can predict responder on 
less than 37.3 s, and have negative correlation with the NSCLC regression rate to CCRT. Cho et al.27 demonstrated 
that the non-necrotic in the well-perfused region has a “rapid uptake and rapid washout” enhancement mode in 
the Dunning R3327-AT prostate tumor of rat, whereas the hypoxic regions, typically characterized by reduced 
vascularization, showed a delayed contrast enhancement corresponding to a delay in signal build-up and also to 
a delay in washout. In necrotic regions of the tumor, the time-dependent increase in the MR signal was slowest, 
and no washout could be observed for the duration of the MR experiment. Another study claimed the perfusion 
indices MTT was correlated with the micro-vascular density of malignant solitary pulmonary nodules42, also 
supports our results. BF has a P value 0.07, which is very close to 0.05. Hypothetically, perfusion and permeability 
can all be helpful in performing tumor response prediction by providing blood supply information. By using a 
larger data set, it is possible that BF can show statistical difference.
Heterogeneity analysis is realized by using Standard Deviation (SD). It was reported that describing heter-
ogeneity within tumors can providing more understanding of tumor biology19. Aerts et al.43 demonstrated that 
intratumour heterogeneity was strongly prognostic, and was associated with gene-expression profiles. de Langen 
et al.23 indicated that patients with an increase of more than 15% in the SD of tumor Ktrans values, which mean an 
increase of intra-tumor heterogeneity, predicted for treatment failure. In our study, it showed that lower values 
SD of Ve, MTT and BV, mean relatively homogeneous of these parameters and predict a better prognosis. It is 
interesting to mention that heterogeneity analysis of Ktrans and Kep did not show any value. However, previous 
non-valuable parameter BV became useful by using SD analysis, which demonstrated that heterogeneity analysis 
can reveal previously hidden useful information.
Compared between perfusion and permeability parameters in correlations with tumor regression rate, sta-
tistical results showed that permeability (Ktrans, Kep, Ve and Ve_SD) are excellent (P < 0.05) predictor, whereas 
perfusion parameters are not related (P > 0.05) at all. Although, the mechanism behind the difference is not quite 
clear, this definitely raise the importance of using permeability as a predictor in the future.
There are several limitations in our study. Firstly, the tumor analysis on a single slice is sub-optimal. However, 
the tumor response assessment was performed according to the RECIST1.1 criteria, which measure the larg-
est diameter of the largest slice. Therefore, at the current stage we just analyzed the largest slice. Secondly, 
the follow-up period was short, and we did not evaluate clinical end points such as overall survival rate or 
progression-free survival. Thus, we did not evaluate the correlation between pre-therapy DCE-MRI parameters 
and these endpoints. Thirdly, a comparison between perfusion and permeability parameters between tumor and 
healthy lung tissue would be informative for a baseline study.
In conclusion, our preliminary results suggest that baseline perfusion and permeability parameters calculated 
from T1W DCE-MRI were seen to be a viable tool for predicting the early response after CCRT of advanced 
NSCLC. Pretreatment mean value of Ktrans, Kep, Ve and MTT is potentially useful for predicting treatment 
response, where Ve has the best differentiation ability. Heterogeneity analysis on perfusion and permeability 
parameters showed that standard deviation of Ve, BV and MTT also demonstrated good prediction ability. 
Permeability (Ktrans, Kep, Ve and Ve_SD) can be used for predict tumor regression rate.
References
1. Ridge, C. A., McErlean, A. M. & Ginsberg, M. S. Epidemiology of Lung Cancer. Semin Intervent Radiol 30, 93–82 (2013).
2. McCloskey, P., Balduyck, B., Van Schil, P. E., Faivre-Finn, C. & O’Brien, M. Radical treatment of non-small cell lung cancer during 
the last 5 years. Eur J Cancer 49, 1555–1564 (2013).
3. Jensen, R. L. et al. Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in 
specific areas of intratumoral microenvironment and is predictive of patient outcome. Neuro Oncol 16, 280–291 (2014).
4. Thews, O., Riemann, A., Nowak, M. & Gekle, M. Impact of hypoxia related tumor acidosis on cytotoxicity of different 
chemotherapeutic drugs in vitro and in vivo. Adv Exp Med Biol 812, 51–58 (2014).
5. Zahra, M. A., Hollingsworth, K. G., Sala, E., Lomas, D. J. & Tan, L. T. Dynamic contrast enhanced MRI as a predictor of tumour 
response to radiotherapy. Lancet Oncol 8, 63–74 (2007).
6. Li, S. P. & Padhani, A. R. Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging 35, 745–763 (2012).
7. Naish, J. H. et al. Modeling of contrast agent kinetics in the lung using T1-weighted dynamic contrast-enhanced MRI. Magn Reson 
Med 61, 1507–1514 (2009).
8. van Elmpt, W. et al. Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of 
tumour hypoxia, metabolism and perfusion. Eur J Nucl Med Mol Imaging 43, 240–248 (2016).
9. Rueckert, D. et al. Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging 
18, 712–721 (1999).
10. Coselmon, M. M., Balter, J. M., McShan, D. L. & Kessler, M. L. Mutual information based CT registration of the lung at exhale and 
inhale breathing states using thin-plate splines. Med Phys 31, 2942–2948 (2004).
11. Uneri, A. et al. Deformable registration of the inflated and deflated lung in cone-beam CT-guided thoracic surgery: initial 
investigation of a combined model-and image-driven approach. Med Phys 40, 017501 (2013).
www.nature.com/scientificreports/
8Scientific RepoRts | 6:35569 | DOI: 10.1038/srep35569
12. Zöllner, F. G. et al. Assessment of 3D DCE-MRI of the kidneys using non-rigid image registration and segmentation of voxel time 
courses. Comput Med Imaging Graph 33, 171–181 (2009).
13. Kudo, K. et al. Accuracy and Reliability Assessment of CT and MR Perfusion Analysis Software Using a Digital Phantom. Radiology 
267, 201–211 (2013).
14. Chen, J., Yao, J. & Thomasson, D. Automatic determination of arterial input function for dynamic contrast enhanced MRI in tumor 
assessment. Med Image Comput Comput Assist Interv 11, 594–601 (2008).
15. Huang, W. et al. The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced 
Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge. Tomography 2, 56–66 (2016).
16. Tofts, P. S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7, 91–101 (1997).
17. Fieselmann, A., Kowarschik, M., Ganguly, A., Hornegger, J. & Fahrig, R. Deconvolution-Based CT and MR Brain Perfusion 
Measurement: Theoretical Model Revisited and Practical Implementation Details. Int J Biomed Imaging 2011, 467563 (2011)
18. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45, 
228–247 (2009).
19. O’Connor, J. P. et al. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res 
21, 249–257 (2015).
20. Yang, C., Karczmar, G. S., Medved, M. & Stadler, W. M. Estimating the arterial input function using two reference tissues in dynamic 
contrast-enhanced MRI studies: fundamental concepts and simulations. Magn Reson Med 52, 1110–1117 (2004).
21. Parker, G. J. et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input 
function for dynamic contrast-enhanced MRI. Magn Reson Med 56, 993–1000 (2006).
22. Li, X. et al. A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in 
human breast cancer. Phys Med Biol 56, 5753–5769 (2011).
23. de Langen, A. J. et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived 
from PET and dynamic contrast-enhanced MRI. J Nucl Med 52, 48–55 (2011).
24. Chang, Y. C. et al. Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line 
bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imagin 36, 387–396 (2012).
25. Kelly, R. J. et al. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell 
lung cancer receiving sorafenib. Clin Cancer Res 17, 1190–1199 (2011).
26. Choyke, P. L., Dwyer, A. J. & Knopp, M. V. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance 
imaging. J Magn Reson Imaging 17, 509–520 (2003).
27. Cho, H. et al. Noninvasive multimodality imaging of tumor microenvironment: Registered dynamic magnetic resonance imaging 
and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia 11, 247–259, 242p following 
259 (2009).
28. Justus, C. R., Dong, L. & Yang, L. V. Acidic tumor microenvironment and pH-sensing G protein-coupled receptors. Front Physiol 4, 
354 (2013).
29. Mayer, A. & Vaupel, P. Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance 
to therapy? Adv Exp Med Biol 789, 203–209 (2013).
30. Halle, C. et al. Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced 
MRI. Cancer Res 72, 5285–5295 (2012).
31. Zahra, M. A. et al. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements 
predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys 74, 766–773 (2009).
32. Ahn, S. J. et al. Quantitative assessment of tumor responses after radiation therapy in a DLD-1 colon cancer mouse model using 
serial dynamic contrast-enhanced magnetic resonance imaging. Yonsei Med J 53, 1147–1153 (2012).
33. Gu, J. et al. Combined use of 18F-FDG PET/CT, DW-MRI, and DCE-MRI in treatment response for preoperative chemoradiation 
therapy in locally invasive rectal cancers. Clin Nucl Med 38, e226–e229 (2013).
34. Ellingsen, C., Hompland, T., Galappathi, K., Mathiesen, B. & Rofstad, E. K. DCE-MRI of the hypoxic fraction, radioresponsiveness, 
and metastatic propensity of cervical carcinoma xenografts. Radiother Oncol 110, 335–341 (2014).
35. Kim, J. H. et al. Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy. Eur 
Radiol 22, 2533–2539 (2012).
36. Cheng, J. C. et al. Early detection of Lewis lung carcinoma tumor control by irradiation using diffusion-weighted and dynamic 
contrast-enhanced MRI. PLoS One 8, e62762 (2013).
37. O’Connor, J. P. et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab 
and FOLFOX-6. Br J Cancer 105, 139–145 (2011).
38. Anderson, A. W. et al. Effects of cell volume fraction changes on apparent diffusion in human cells. Magn Reson Imaging 18, 689–695 
(2000).
39. Ohno, Y. et al. Diffusion-weighted MRI versus 18F-FDG PET/CT: Performance as predictors of tumor treatment response and 
patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. AJR Am J Roentgenol 198, 75–82 (2012).
40. Padhani, A. R. & Koh, D. M. Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am 19, 
181–209 (2011).
41. Yabuuchi, H. et al. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic 
and diffusion-weighted MR imaging. Radiology 261, 598–604 (2011).
42. Mamata, H. et al. Clinical application of pharmacokinetic analysis as a biomarker of solitary pulmonary nodules: dynamic contrast-
enhanced MR imaging. Magn Reson Med 68, 1614–1622 (2012).
43. Aerts, H. J. et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5, 
4006 (2014).
Acknowledgements
We would like to express our gratitude to the technical support and assistance from Dr. Huang, Ning from 
Life Science, GE Healthcare China. This work was funded by the National High Technology Research and 
Development Program of China (863 Program, Grant No. 2014AA020602) and The Innovation Funds of Peking 
Union Medical College (Grant No. 2013-1002-20).
Author Contributions
Conception and design: N.W., H.Oy., X.T., L.W., F.Y. and Z.S. Development of methodology: N.W., H.Oy., X.T., 
L.W., F.Y. and Z.S. Acquisition of data (acquired and managed patients, image registration, etc.): X.T., Z.H., Y.T., 
Y.M., X.X. and Z.S. Analysis and interpretation of data (e.g., image analysis, tumor response assessment, statistical 
analysis): X.T., L.L., Y.S., Z.H., Y.T., Y.M., N.W., H.Oy., T.L. and X.X. Writing, review, and/or revision of the 
manuscript: X.T., N.W., H.Oy., Z.S., T.L. and L.W. Administrative, technical, or material support: N.W., Z.S. and 
T.L. Study supervision: N.W., H.Oy. and T.L.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:35569 | DOI: 10.1038/srep35569
Additional Information
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Tao, X. et al. DCE-MRI Perfusion and Permeability Parameters as predictors of tumor 
response to CCRT in Patients with locally advanced NSCLC. Sci. Rep. 6, 35569; doi: 10.1038/srep35569 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2016
